Results 91 to 100 of about 2,385 (197)
REC: Interventional Cardiology (English Ed.), 2020 During the second half of 2019, cangrelor started selling in our country, a “new” antiplatelet drug with especial pharmacological properties that make it especially appealing for the management of certain clinical situations in the percutaneous coronary ...
José Luis Ferreiro +1 more
doaj +1 more source
Cangrelor - rising from the ashes: a phoenix story [PDF]
, 2016 Cangrelor is a novel intravenous antiplatelet agent that has been approved for usage in the setting of percutaneous coronary revascularization in patients with acute coronary syndrome. The drug was evaluated in three major trials namely Champion-Platform,
George, Melvin +2 more
core +2 more sources
Acute myocardial infarction complicating ischemic stroke: is there room for cangrelor?
Platelets, 2020 Acute myocardial infarction (AMI) complicating ischemic stroke is a well known and undertreated event. A conservative management is not infrequent in these settings, due to the fear of hemorrhagic complications related to antithrombotic therapy. Notably,
Nuccia Morici +9 more
doaj +1 more source
Cangrelor for the management and prevention of arterial thrombosis [PDF]
, 2016 INTRODUCTION: Despite advances in antiplatelet therapy, the optimum antithrombotic regimen during percutaneous coronary intervention (PCI) remains to be determined.
Storey, R.F., Sinha, A.
core +1 more source
The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor [PDF]
, 2010 Novel P2Y12 inhibitors are in development to overcome the occurrence of atherothrombotic events associated with poor responsiveness to the widely used P2Y12 inhibitor clopidogrel.
van Werkum, JW +10 more
core +1 more source
Frontiers in Cardiovascular MedicineCangrelor, a potent intravenous P2Y12 platelet inhibitor, has demonstrated effectiveness in reducing ischemic events without a corresponding increase in severe bleeding during percutaneous coronary intervention, as evidenced by the CHAMPION-PHOENIX trial.
Abdelrahman Ali +9 more
doaj +1 more source
Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
Frontiers in Cardiovascular Medicine, 2019 Antiplatelet therapy with P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor, cangrelor) is a cornerstone of medical therapy after percutaneous coronary interventions.
Małgorzata Ostrowska +9 more
doaj +1 more source
Combining the $P2Y_{12}$ antagonist cangrelor with energy metabolism inhibitors has a synergistic antiaggregatory effect [PDF]
Antiplatelet therapy represents a key strategy to reduce cardiovascular events related to thrombosis. This study aimed to test whether inhibiting platelet energy metabolism would enhance the antiaggregatory action of cangrelor.
Kaczara, Patrycja +7 more
core +1 more source
Cangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX) [PDF]
, 2014 Platelet inhibition is the main goal of ancillary pharmacologic therapy during percutaneous coronary interventions (PCI). Thienopyridines and ticagrelor are oral drugs developed for this purpose. Cangrelor is an intravenous, non-thienopyridine antagonist
Rizzotti D., Marino M., Leonardi S.
core +1 more source